ArticleLiver cancer2018

Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study.

Masatoshi Kudo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.